NewslettersHuman Immunology NewsFunctional Landscapes of POLE and POLD1 Mutations in Checkpoint Blockade-Dependent Antitumor ImmunityBy Danielle Corrigan - July 12, 20220340Patients with POLE/POLD1 mutated tumors harboring telltale mutational signatures responded better to immune checkpoint blockade therapy than patients harboring wild-type or signature-negative tumors.[Nature Genetics]Abstract